Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

BioStem Technologies Inc. (OTC:BSEM) Stock Extends Rally: Here is Why

There were some stocks that emerged as notable gainers on Tuesday, and one of those was the BioStem Technologies Inc. (OTC:BSEM), which ended up with gains of 5%. The rally came about following a key announcement from the medical technology company.

BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions

The company announced yesterday that the CMS (Center for Medicare Services) set up national pricing for Vendaje AC, its allograft offering, in all the MAC (Medicare Administrative Contractor) regions. The pricing announcement had gone into effect on October 1 and would allow BioStem Technologies to start the marketing of its product in all the MAC zones.

Key Information

The company would work on the commercialization of the Vendaje AC product through Venture Medical LLC. Venture Medical is a leading commercialization services provider operating in the United States wound care market and boasts of a dedicated sales team in the wound care space. It is also important to note that currently it is involved in collaboration with BioStem Technologies for the successful launch of the product AmnioWrap2.

Through the pricing approval, Vendaje would instantly become more accessible to a larger pool of patients across the United States. The development was also in alignment with BioStem Technologies’ mission to improve the level of wound care in the United States. It is going to be interesting to see if the stock records more gains today or not.

CEO Quote

Jason Matuszewski, CEO of BioStem Technologies Inc., commented: “With CMS’s national pricing approval, Vendaje AC is now accessible to more patients across the country, representing a major milestone in our mission to improve advanced wound care. We are thrilled to partner with Venture Medical to bring Vendaje AC to a broader audience. Their expertise in the wound care market will be invaluable as we continue to deliver innovative solutions for patients in need.”

Fundamentals

P/E Ratio38.30
PEG Ratio0.16
Price to Book13.90
Price to Cash Flow36.9405
Price to Free Cash Flow39.4549
Total Sales (TTM)131.44 M
Revenue per Share (TTM)6.28
Shares Outstanding16.338 M
Share Float (%)11.82 M (72.36%)

Published by Jon Williams

Jon graduated from the University of Michigan with a degree in finance. He is an avid investor and enjoys reporting on the markets. When he is not in front of a computer he enjoys playing golf and watching basketball.

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
*By submitting your information you agree to the terms of our Privacy Policy. You will receive the DRP Journal newsletter, and third party offers. You can unsubscribe anytime by selecting unsubscribe at the bottom of our emails.